此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 NBI-921352 作为 SCN8A-DEE 受试者辅助治疗的安全性和耐受性的扩展研究

2026年11月10日 更新者:Neurocrine Biosciences

一项前瞻性、长期、干预性、主动扩展研究,以评估 NBI-921352 作为 SCN8A 发育和癫痫性脑病综合征 (SCN8A-DEE) 受试者辅助治疗的安全性和耐受性

Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

研究概览

研究类型

介入性

注册 (实际的)

8

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94143
        • UCSF Medical Center
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • Children's National Hospital
    • New York
      • Rochester、New York、美国、14642
        • University of Rochester
    • Texas
      • Fort Worth、Texas、美国、76104
        • Cook Children's Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 22年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

For Participants Who Participated in NBI-921352-DEE2012:

  • Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
  • Completed 16 weeks of treatment in Study NBI-921352-DEE2012.
  • Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
  • Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.

For Participants Who did not Participate in NBI-921352-DEE2012:

  • Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
  • Be a male or female 2 to 21 years of age, inclusive.
  • Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
  • Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
  • Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
  • Have failed to achieve seizure freedom with at least 2 ASMs.
  • Have a body weight of at least 10 kilograms.

Key Exclusion Criteria

For Participants Who Participated in NBI-921352-DEE2012:

- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.

For Participants Who did not Participate in NBI-921352-DEE2012:

  • Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
  • Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
  • Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
  • Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
  • Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
  • Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
  • Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
  • Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NBI-921352

NBI-921352 administered for up to 164 weeks.

Administered orally

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
大体时间:Day 1 to Week 168
Day 1 to Week 168

次要结果测量

结果测量
大体时间
Percentage Change from Baseline in 28-day Seizure Frequency for Countable Motor Seizures
大体时间:Baseline, up to Week 162
Baseline, up to Week 162

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Development Lead、Neurocrine Biosciences

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年7月12日

初级完成 (实际的)

2025年11月12日

研究完成 (实际的)

2025年11月12日

研究注册日期

首次提交

2022年1月26日

首先提交符合 QC 标准的

2022年1月26日

首次发布 (实际的)

2022年2月7日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • NBI-921352-DEE2013
  • 2021-004393-62 (EudraCT编号)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅